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Abstract:  Objective:  Anti-TNF agents (etanercept, infliximab and adalimumab) are widely used in inflammatory 
conditions, such as rheumatoid arthritis; however, they are not without side effects, potentially including lymphoma. We 
compared Epstein-Barr virus (EBV) levels in patients with inflammatory arthritis taking biologic agents and controls 
matched for disease, age, gender and disease duration who were biologic naïve. Secondly, we determined the risk of 
reactivation of EBV in patients taking biologics. 
Methods: One hundred and twenty-two patients were recruited and blood samples were collected. Immunoglobulin G 
(IgG) antibody to EBV was analysed using enzyme-linked immunosorbent assay. EBV DNA was analysed using 
polymerase chain reaction (PCR) on all positive IgG samples. Quantitative measures of viral DNA were made and 
expressed as copies/reaction volume. Reactivation was defined as the presence of viral DNA in the plasma and PCR 
activity was evaluated between 6 and 18 months after anti-TNF therapy. 
Results: IgG for EBV was detected in 98% of controls and 90% of cases. Viral reactivation related to EBV was not 
observed in this study. There was one patient who tested positive for EBV using PCR, but upon confirmatory testing, this 
sample was actually negative. No samples were positive on PCR at the follow-up time points.  
Conclusion: There was a high rate of EBV IgG in the cases and controls in this study. Given the small sample size and 
timeframe for this study, treatment with anti-TNF agents does not seem to lead to EBV reactivation, and thus, this is likely 
not a mechanism for the development of lymphoma in patients taking biologics. 
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INTRODUCTION 
  Rheumatoid arthritis (RA) is characterized by a systemic 
inflammatory disorder that causes synovitis leading to joint 
destruction. Research into the pathogenesis has shown that 
an abnormal immune response in a genetically predisposed 
patient is the hallmark of the disease. Specifically, tumor 
necrosis factor (TNF)-alpha () has been shown to be 
involved in the inflammatory cascade due to the production 
of many cytokines and studies have demonstrated clinical 
benefit with TNF- blockade [1-4]. In patients who have not 
responded to traditional disease-modifying agents (DMARDs), 
these biologic agents have become an important option in the 
rheumatologist’s repertoire to treat RA [3,5,6]. There are 
three anti-TNF drugs on the market in Canada, etanercept, 
infliximab and adalimumab, and all target the pro-
inflammatory cytokine, tumour necrosis factor. Infliximab is 
a mouse human chimeric antibody to TNF-alpha and 
adalimumab is a fully human chimeric antibody. Etanercept 
is a fusion protein that binds TNF and has also been shown 
to neutralize lymphotoxin alpha which is associated with   
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tumour growth control [5]. These agents have proven efficacy 
in the treatment of RA, psoriatic arthritis and ankylosing 
spondylitis [5]. However, there are important clinical 
concerns about their side effects including risk of infection, 
lymphoma, reactivation of tuberculosis, and demyelinating 
syndromes [6-10]. Evidence from clinical trials and post-
marketing surveys suggest that there may be an increased 
risk of lymphoma, however the mechanism for oncogenicity 
is not entirely known [11, 12]. Wolfe and Michaud published 
data on 18,574 patients with RA in which there were 29 
lymphomas; the standardized incidence ratio (SIR) for 
lymphoma was 1.9 (95% CI 1.3-2.7). In patients receiving 
biologics, the SIR was 2.9 (95% CI 1.7-4.9) [7]. However, 
the confidence intervals overlap and it is difficult to know if 
disease severity is the added risk that further heightens the 
observed number of lymphomas in anti-TNF treatment 
above overall RA background risk. 
  One of the proposed mechanisms for the observed 
increased risk of malignancy is viral reactivation of Epstein 
Barr virus, due to different forms of immunosuppression 
including drug treatments or disease states. The risk of 
reactivation of certain viruses, including EBV, has been 
shown in other inflammatory conditions and in the transplant 
setting, however, few studies have determined the effect on 
viral titers of EBV after treatment with anti-TNF [13, 14]. 
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Barr virus (EBV) polymerase chain reaction (PCR) in 
patients treated with anti-TNFs and matched controls and a 
prospective study of potential PCR reactivation in patients 
starting anti-TNF treatment. 
MATERIALS AND METHODOLOGY 
Study Population and Protocol 
  The study population consisted of patients seen at St. 
Joseph’s Hospital Rheumatology clinic, affiliated with the 
University of Western Ontario, which services a large referral 
area of approximately one million. The data are from patients 
who were seen serially by a rheumatologist and diagnosed with 
rheumatoid arthritis (meeting ACR criteria), ankylosing 
spondylitis (AS), psoriatic arthritis (PsA) or other inflammatory 
arthritis. AS was diagnosed according to the Modified New 
York Criteria (1984) where definite ankylosing spondylitis was 
present if the radiologic criterion was present in addition to at 
least one clinical criterion (which included low back pain, 
limitation in lumbar spine motion or limitation in chest 
expansion) [15]. Psoriatic arthritis was diagnosed clinically 
using the ClASsification of Psoriatic ARthritis (CASPAR) 
criteria (inflammatory joint disease with at least 3 points from 
the following features: current psoriasis; a history of psoriasis; a 
family history of psoriasis; dactylitis; juxta-articular new bone 
formation; rheumatoid factor negativity; and nail dystrophy) 
[16]. All diagnoses were made by a rheumatologist. Patients 
were recruited over a 6-month period and had at least two 
consecutive visits within an 18 month period. The study design 
consisted of two parts: one part was prospective and the second 
was a case control study. For the prospective study, patients 
with an inflammatory arthritis (RA, PsA, AS or other 
inflammatory arthritis) who were about to start anti-TNF 
treatment for their rheumatologic disease were recruited. 
Patients who were previously exposed to anti-TNF treatments 
or other biologics were excluded. For the case control study, 
similar diagnostic criteria were used to include patients, and 
patients were either taking a biologic (cases) or had never been 
exposed to a biologic treatment (controls). Patients were 
required to be treated with an anti-TNF biologic (etanercept, 
infliximab or adalimumab) for a minimum of two months. The 
cases were matched according to age, disease type, disease 
duration (within three years) and gender. The exclusion criteria 
were those patients not willing or unable to give consent. The 
type of treatment, including biologics, DMARDs and steroids, 
as well as baseline Health Assessment Questionnaire (HAQ) 
score, was recorded at the initial visit. Ethics approval was 
obtained locally through The University of Western Ontario 
Health Sciences Research Ethics Board. 
  After signing a consent form, IgG levels of EBV were tested 
in patients receiving biologics (cases) compared to patients who 
were biologic naïve (controls). All samples were run at the same 
time with the lab unaware of exposure status. Antibody (IgG 
class) to EBV viral capsid antigen was detected using enzyme-
linked immunosorbent assay technique. Viral load EBV DNA 
was amplified with specific primers using PCR on all IgG 
positive samples. No one had a history of a recent EBV 
infection; therefore, IgM was not tested. 
Analysis 
  The frequency of EBV positivity (IgG) was measured 
and expressed as a percentage. EBV IgG > 1.1 was defined 
as a positive result; 1.1 was defined as an arbitrary cutoff 
measurement as positive according to the manufacturer 
(Trinity Biotech, Canada). EBV status was compared 
between cases and controls in the entire group as well as 
disease-based subsets. Chi square tests were used for the 
analysis between cases and controls. For the prospective 
study the proportion of patients who were sero-converting 
and with PCR activity between 6 and 18 months after anti-
TNF therapy was started was determined. Viral reactivation 
was defined as the presence of viral DNA in the plasma. 
Viral DNA was expressed as a quantitative variable using 
PCR as number of copies detected per reaction volume. P 
values of < 0.05 were considered statistically significant. 
RESULTS 
  The mean age was 60 years (SD 13.2) and the mean 
disease duration was 11.7 years. The majority of patients 
were women (83%). A total of 122 patients were recruited 
and had samples analysed for this study (72 taking anti-TNF 
and 50 controls). Ninety-nine patients had RA, 6 had AS, 12 
had PsA, and there were 5 patients with other inflammatory 
arthritis. In terms of immunosuppressant therapy, the 
majority of patients (92%) were using DMARD therapy, 
50% non-steroidal anti-inflammatory drugs and 16% 
prednisone. The baseline HAQ score was 0.97 +/- 0.76 (SD), 
with 0 corresponding to no disability and 3 to severe 
disability. None of the patients reported a history of 
malignant conditions nor did any of the patients have a 
history of EBV related infection. 
  For the viral studies, 93% were seropositive for IgG EBV 
(98% in the controls, and 90% in the cases) and there was no 
significant difference between cases and controls (p = 0.14). 
The results were similar according to each disease subtype; 
the majority of patients were seropositive for IgG EBV. 
Table 1 provides the percentage of patients with positive IgG 
EBV in cases and controls and according to the type of 
disease. Although some disease subsets are limited by 
smaller sample sizes, the data suggest that the majority of 
patients are seropositive for EBV. For the prospective study, 
quantitative PCR was only positive in one sample at 159 
copies in a male with RA taking infliximab, but upon 
confirmatory testing of the same sample, it was actually 
negative. Fig. (1) shows the real time PCR amplification 
curve for EBV in a positive representative sample compared 
to a patient sample, which is negative. The results did not 
differ according to disease subtype (RA, PsA, AS or other 
inflammatory arthritis), as all of the viral PCR tests were 
negative. The rate of EBV in our centre (as known by 
transplant donors) is > 90%. In the prospective study, all 
patients were EBV (IgG) positive; however, no one had 
positive viral PCR at the follow-up time points (6 months 
and 18 months). 
DISCUSSION 
  It has been shown that various types of immunosuppression 
may induce viral reactivation, in particular EBV. Moreover, 
this reactivation of latent EBV may lead to the development 
of lymphoma. Our results show that the prevalence of EBV 
in this rheumatology practice (93%) was similar to that seen 
in the transplant population at our centre. The positivity for 
EBV seen in this study is higher than expected, but unrelated 
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time they reach adulthood and the virus remains latent and 
resides in B lymphocytes. Healthy carriers can have 
approximately 1 to 50 infected cells per million leukocytes 
and latent infection is thought to be due to the limited 
expression of viral proteins to avoid immune recognition and 
detection [17]. However, in patients that are 
immunosuppressed a broader spectrum of viral proteins can 
be expressed allowing for further viral replication [17]. 
Patients with RA are considered immunosuppressed, thus 
this may explain the high rate of EBV positivity seen in the 
case control study [11, 12]. 
  The evidence to support an increased risk of lymphoma 
in patients treated with anti-TNF agents is still under 
scrutiny and the mechanism for the contributory role of anti-
TNFs for oncogenicity is speculative [8,14,18]. The findings 
of this study are similar to the data from a study by Torre-
Cisneros [19]. In a cohort of 15 patients with refractory 
forms of RA being treated with infliximab for 6 weeks, there 
was only one patient who developed viral reactivation of 
human herpesvirus (HHV)-6 after the onset of the anti-TNF. 
None of the patients developed reactivation of EBV, even 
though latent EBV virus was detected in 46.6% of patients. 
Our results suggest that anti-TNFs do not increase the risk of 
viral reactivation of EBV, and that there may be other 
mechanisms of immunosuppression related to the 
development of lymphoma in RA patients. 
  The immunosuppressant drugs methotrexate and azathioprine 
have been investigated and may alter immune function and 
Table 1.  Percentage of IgG Positive EBV Patients Between Patients Treated with anti-TNF Agents (Cases) and Controls 
 
Treated with Biologic (Anti-TNF)  Biologic Naive 
 
n  IgG EBV  n  IgG EBV 
p-Value 
Entire Study Population  72  90%  50  98%  0.1 
RA Only  53  91%  46  98%  0.2 
AS Only  6  67%  0  -  - 
PsA Only  9  100%  3  100%  - 
Other Inflammatory 
Arthritis Only 
4 100%  1  100%  - 
RA = rheumatoid arthritis, AS = ankylosing spondylitis, PsA = Psoriatic arthritis. 
 
 
Fig. (1). Real time PCR analysis for quantitative EBV detection. 
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surveillance mechanisms and lead to the development of 
lymphoproliferative disorders in patients with RA. 
Discontinuation of methotrexate has been followed by a 
regression of lymphoma in numerous case reports, thus 
providing some evidence for a link, however there are 
conflicting results [14]. For example, Wolfe and Michaud 
prospectively studied 18,572 patients with RA and did not find 
an increased SIR for lymphoma in patients receiving 
methotrexate compared to those not exposed to methotrexate. In 
our study, the majority of patients were taking a DMARD that 
included methotrexate and this could confer additional 
immunosuppression leading to EBV positivity. There is some 
evidence that Crohn’s patients treated with azathioprine and 6-
mercaptopurine may have an increased risk of developing 
lymphoma. Losco et al. report a case study of a patient with 
Crohn’s disease treated with azathioprine and infliximab who 
developed diffuse large B cell lymphoma and EBV was 
detected (via PCR) in the neoplastic cells [13]. In contrast, the 
degree of immunosuppression to induce viral reactivation of 
EBV was not seen in this study, and there may be some amount 
of immune preservation in these patients that is not seen in other 
populations, such as organ transplantation. 
  In the transplant setting, for example, EBV associated 
post-transplant lymphoproliferative disorders (PTLD) are 
thought to be due to the transformation of the host 
lymphocytes, from the donor organ in EBV-seronegative 
patients, or a combination of donor and recipient EBV 
isolate in seropositive patients [14]. As a result, there is an 
expansion of multiple lineages of EBV transformed B cells, 
and the expression of a number of latent EBV oncogenes. 
This mechanism is supported by the high levels of EBV 
DNA in the cellular and cell-free fractions of blood in 
patients with PTLD [17]. Furthermore, EBV viral load in 
plasma acts as a marker of tumour burden in patients with 
sporadic EBV-related lymphomas including B cell, T cell, 
Natural killer cell and Hodgkin’s subtypes [17]. In this 
mechanism of oncogenicity, the patient’s immune system is 
unable to control latent EBV infection and impaired cellular 
immunity allows for the reactivation of EBV, leading to the 
development of lymphoma. Rohr et al. reported two cases of 
EBV associated lymphomas after solid organ transplant and 
found different EBV expression patterns associated with 
PTLD and infectious mononucleosis [20]. It has also been 
shown that EBV DNA levels increase before a patient 
becomes symptomatic due to PTLD, thus EBV viral load 
testing is done as a screening measure in patients at highest 
risk for PTLD [21]. Overall, the data from the transplant 
population suggests that immunosuppression is a critical risk 
factor for the development of EBV positive lymphomas. It is 
known that RA patients face some impairment in immunity 
that can lead to the development of serious bacterial 
infections and granulomatous infections, however, the 
necessary degree of immunosuppression to lead to an EBV 
associated lymphoma is unknown in this population [6,10]. 
In addition, the specific mechanism of immunosuppression 
has yet to be determined. 
  Limitations to this study should be reviewed and 
understood. First, our study included only several hundred 
patients, and therefore is underpowered to detect an 
excessive risk of a rare event, such as the development of 
lymphoma. The overall risk of lymphoma in patients with 
RA is conflicting in the literature. Wolfe and Michaud have 
attempted to address the possible risk of lymphoma in 
patients with RA using anti-TNF therapy. From the 19,591 
patients in the National Data Bank for Rheumatic Diseases 
(NDB) registry, the authors found that there was no increase 
in the risk of lymphoma in patients treated with anti-TNF 
agents (odds ratio [OR] 1.0, 95% CI 0.6-1.8 [P0.875]) [12]. 
These results are in contrast to a meta-analysis of 
randomized clinical trials (RCT) data conducted by Bongartz 
et al. using infliximab or adalimumab in RA. A total of 10 
lymphomas in 3493 patients treated with anti-TNFs were 
identified compared to no lymphomas in 1,512 non-anti-TNF 
treated patients. The pooled odds ratio for malignancies in 
anti-TNF treated patients was 3.3 (95% CI 1.2-9.1), 
indicating that there was a significantly higher risk of 
malignancy in patients with RA treated with anti-TNF 
therapy [8]. Bongartz et al. recently performed a second 
meta-analysis of RCTs of studies involving etanercept for a 
study duration of 12 weeks. Twenty-six patients in the 
etanercept group were diagnosed with a malignancy 
[incidence rate (IR) 10.47/1000 Patient Years (PY)] 
compared to 7 patients in the control group (IR 6.66/1000 
PY), which was not significantly different between groups 
[22]. In a population based cohort study by Askling et al., 
the risk of lymphoma in patients with RA treated with anti-
TNFs was tripled (SIR = 2.9, 95% CI 1.3 to 5.6) compared to 
the general population, however, when adjusted for sex, age, 
and disease duration, the risk of lymphoma after treatment 
with anti-TNF agents was no higher compared to the other 
RA cohorts [11]. Thus, the risk of lymphoma in patients 
using anti-TNF therapy for RA is still debatable making the 
search for potential mechanisms challenging in this 
population. We note also, that these previous studies have 
focused on the RA population whereas our study includes 
patients with other inflammatory conditions, AS and PsA. 
This heterogeneity within the patient population may have 
affected our results. Another limitation is that our 
observation period of 18 months may have been too short to 
observe viral reactivation of EBV. Given the unknown 
duration of development of EBV related lymphoproliferative 
diseases, it is premature to rule out the potential of EBV 
reactivation as a mechanism for the risk of developing 
lymphoma. As a result, we may have failed to identify some 
of the cases of EBV reactivation and this must be considered 
when interpreting our results. 
CONCLUSION 
  In conclusion, it seems unlikely that EBV is reactivated 
in patients with RA taking anti-TNF agents, given the small 
sample size and relatively short timeframe from the initiation 
of biologic therapy in this study. To understand the potential 
risk of lymphoma in patients with rheumatoid arthritis, the 
degree of immunosuppression necessary to induce viral 
reactivation of EBV must include considerations of the 
underlying disease, other forms of immunosuppressant 
therapy and the exact duration for EBV infection. It appears 
that the patients in this study taking anti-TNFs were not 
completely immunocompetent, but also not as 
immunosuppressed as transplant patients to induce EBV 
reactivation. However, due to the serious implications of 
lymphoma and the lack of long term data with anti-TNF 
therapies, physicians still need to warn patients of the 
potential risk. At present, we would also recommend that 34   The Open Rheumatology Journal, 2009, Volume 3  McKeown et al. 
screening tests for EBV are not necessary in patients with 
inflammatory disorders, such as rheumatoid arthritis, who 
are now candidates for anti-TNF therapies. Finally, future 
studies could help address the pathogenic mechanisms in 
other illnesses associated with anti-TNF therapies, such as 
serious infections and reactivation of tuberculosis to help 
elucidate potential mechanisms of immunosuppression. 
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